Overview


According to FutureWise analysis the market for spinal muscular atrophy treatment in 2023 is US$ 4.6 billion, and is expected to reach US$ 7.92 billion by 2031 at a CAGR of 7.00%.

Rising awareness pertaining to spinal muscular atrophy, soaring initiatives from improving treatment alternatives for rare diseases are some of the crucial factors contributing to the growth of the market. For instance, the U.S FDA awarded an orphan drug license to the collaborative program of SMA Foundation, PTC Therapeutics and Roche named RG7916 for treating spinal muscular atrophy. Furthermore, the growing initiatives implemented by different non-profit and public organizations for creating awareness pertaining to SMA has boosted the spinal muscular atrophy treatment market growth. Additionally, the National Institute for Care and Health Excellence in January 2018, summoned Biogen for submitting a tech appraisal for Spinraza. NHs and NICE have agreed for a long-term plan regarding Biogen’s Spinraza. Such a wide range of products for treating SMA has propelled the proliferation of the market.

  • Biogen,
  • Ionis Pharmaceuticals Inc.,
  • F. Hoffmann La Roche Ltd.,
  • Avenis Inc.,
  • Novartis AG,
  • Cytokinetics Inc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Treatment

  • Drugs
  • Gene Therapy

By Route of Administration

  • Oral
  • Intrathecal

By Disease Type

  • Type 1
  • Type 2
  • Type 3
  • Type 4

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

The market is classified into treatment, route of administration, disease type and region. The treatment segment is fragmented into gene therapy and drugs. The gene therapy segment is anticipated to hold the largest spinal muscular atrophy treatment market share as it is a viable option than drugs. Additionally, Spinraza is the only drug that received an FDA approval for SMA treatment in recent times which is why it is expected that the drugs segment is predicted to grow at a substantial rate during the forecast period. The route of administration segment is classified into oral and intrathecal. The intrathecal segment is anticipated to lead the market as drugs like Spinraza are provided intrathecally. Additionally, no new drugs are expected to be launched till the end of 2021 which shall maintain its market dominance.

The disease type segment is categorised into type 1, type 2, type 3 and type 4. The type 1 segment is estimated to lead the market owing to its rising prevalence. Furthermore, companies are emphasizing on developing drugs for treating type 1 SMA and this shall boost the segment growth. Similarly, there have been significant progress in the development of novel therapies. For instance, AveXis Inc. have developed a gene therapy, AVXS-101, which has been tested clinically for safety evaluations. Similarly, Novartis AG’s LMI07 also focusses on treating type 1 SMA.

The North America region is predicted to dominate the market as the Unites States market generates maximum revenue amongst all regions. Furthermore, crucial players like Biogen are in the region as they have developed important drugs like Spinraza. Moreover, there has been a rise in the number of initiatives conducted by private and public bodies for creating awareness coupled with growing investments in research and development activities related to spinal muscular atrophy.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the global spinal muscular atrophy treatment market By Treatment, By Route of Administration, By Disease Type and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
  • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction

    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders

  • 2.   Research Methodology

    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study

  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Spinal Muscular Atrophy Treatment Market Variables, Trends and Scope

    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework on Country Level
         6.1 . Reimbursement Framework
         6.2 . Standards and Compliances

  • 5.   Market Overview

    •   1. Market Dynamics
         1.1. Market Driver Analysis
         1.2. Market Restraint Analysis
         1.3. Industry Challenges

  • 6.   Spinal Muscular Atrophy Treatment Market Analysis tools

    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from new entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social landscape
         2.4. Technology landscape
         2.5. Legal Landscape

  • 7.  Spinal Muscular Atrophy Treatment Market, By Treatment Historical Analysis and Forecast 2023-2031 (USD million)

    •   1. Drugs
        2. Gene Therapy

  • 8.   Spinal Muscular Atrophy Treatment Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD million)

    •   1. Oral
        2. Intrathecal

  • 9.   Spinal Muscular Atrophy Treatment Market, By Disease Type Historical Analysis and Forecast 2023-2031 (USD million)

    •   1. Type 1
        2. Type 2
        3. Type 3
        4. Type 4

  • 10.   North America Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Mn) Analysis By Country, 2017-2022
         2.1. U.S.
         2.2. Canada
         2.3. Mexico
         2.4 . Rest of North America
        3. Market Size (USD Mn) Forecast for North America 2023-2031

  • 11.   Latin America Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Regional Market Trends
        3. Historical Market Size (US$ Mn) Analysis By Country, 2017-2022
         3.1. Brazil
         3.2. Uruguay
         3.3 . Argentina
         3.4. Rest of Latin America
        4. Market Size (US$ Mn) Forecast for Latin America 2023-2031

  • 12.  Europe Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (US$ Mn) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5 . Switzerland
         2.6. Spain
         2.7. Russia
         2.8. Poland
         2.9. Rest of Western Europe
        3 . Market Size (US$ Mn) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Mn) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. Singapore
         2.4. Korea
         2.5. India
         2.6. Australia and New Zealand
         2.7. ASEAN
         2.8. Rest of Asia Pacific
        3. Market Size (US$ Mn) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Mn) Analysis By Country, 2017-2022
         2.1. UAE
         2.2. South Africa
         2.3. Egypt
         2.4. Saudi Arabia
         2.5. Rest of MEA
        3. Market Size (US$ Mn) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts)

    •   1. Biogen
         1.1. Company Overview (HQ, Business Segments, Employee Strength)
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Ionis Pharmaceuticals Inc.
         2.1. Company Overview (HQ, Business Segments, Employee Strength)
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. F. Hoffmann La Roche Ltd.
         3.1. Company Overview (HQ, Business Segments, Employee Strength)
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Avenis Inc.
         4.1. Company Overview (HQ, Business Segments, Employee Strength)
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Novartis AG
         5.1. Company Overview (HQ, Business Segments, Employee Strength)
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Cytokinetics Inc.
         6.1. Company Overview (HQ, Business Segments, Employee Strength)
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client

Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 141 628 9353
  • US : +1 347 709 4931

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11